# Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients

> **NCT03002064** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 358 (estimated)

## Conditions studied

- Esophagus Cancer
- Chemotherapy Effects

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Fluorouracil
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT03002064
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2019-12
- **Final completion:** 2020-12
- **Target enrollment:** 358 (ESTIMATED)
- **Last updated:** 2016-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03002064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03002064, "Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03002064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*